

**MINUTES OF THE October 11, 2011
PHARMACY AND THERAPEUTICS (P&T) COMMITTEE MEETING**

MEMBERS ATTENDING: Deborah Minor, Pharm.D. (Chair); Hosan Azomani, M.D.; Anne Norwood, Ph.D.; Sharon Dickey, Pharm.D.; Ryan Harper, Pharm.D.; Lonnie Hicks, R.Ph.; Carol Tingle, M.D.; Geri Lee Weiland M.D.; Wilma Wilbanks, R.Ph.; Lee Voulters M.D., John Mitchell, M.D. and Billy Brown, Pharm.D.

Also present: Judith Clark, R.Ph., Pharmacy Director, DOM; Terri Kirby, R.Ph., DOM; Shannon Hardwick, R.Ph. DOM; Rick Pope, Pharm.D., Clinical Account Manager, Provider Synergies. Leslie Leon, Pharm.D. ACS-Xerox, Kyle Null, Pharm.D., University of Mississippi School of Pharmacy.

MEMBERS ABSENT: None

CALL TO ORDER: Dr. Minor called the meeting to order.

INTRODUCTIONS: Ms. Clark welcomed attendees to the meeting including the audience, vendors, committee members and Division of Medicaid staff. She introduced new Committee member Anne Norwood, FNP, Ph.D. and welcomed her to the Committee. She requested that everyone at the table introduce themselves. She thanked the Committee members for their background work, their diligence as well as their public work. Ms. Clark gave a special thanks to Mr. Delvin Taylor and Stacy Turner of the DOM staff for all their work in preparation for the meeting. Ms. Clark thanks the remainder of the DOM staff for their hard work and dedication. Ms. Clark then reintroduced Dr. Leslie Leon of ACS, Dr. Kyle Null of the University of Mississippi DUR project and Dr. Rick Pope of Provider Synergies.

ADMINISTRATIVE MATTERS: Ms. Clark outlined procedural and safety guidelines for the meeting. She noted that the P&T Committee is an advisory committee and that the DOM has the final say regarding the PDL. She stated that the minutes from this and each P&T Committee meeting would be posted to the DOM website within 30 days of the meeting. The final approved PDL decisions for classes reviewed at this and each meeting will be posted to the website no later than 30 days before implementation; implementation of the classes reviewed at this meeting will be on January 1, 2012.

Ms. Clark reminded audience members of the sign in requirements as well as the time limitations for speakers and advocates. Advocates will receive five minutes while manufacturer representatives will receive three minutes per drug, not per speaker. There are also no handouts or brochures to be distributed at the meeting.

Ms. Clark reminded all in attendance of the requirements to keep the building clean and that there was not to be any food or drink in the room except for Committee members. Finally, Ms Clark reviewed the emergency procedures for the building and measures to be taken in the event of an emergency.

Ms. Clark said that, due to the current DOM workload, she is not accepting appointments with pharmaceutical manufacturers at this time. She stated that she may begin doing so when the department's workload decreases.

Ms. Clark once again thanked the Committee members for their service and diligence and closed her remarks.

Finally, an election of new committee officers was held. Ms. Clark reminded the committee this occurs every two years. Dr. Mitchell was nominated as Committee Chair and was accepted by acclamation. Ms. Wilbanks was nominated as co-chair with Ms. Wilbanks accepting the position and accepted again by acclamation.

APPROVAL OF SEPTEMBER 13, 2011 MEETING MINUTES: Mr. Hicks noted the minutes indicated he was present at the September meeting when in fact he was absent. With the single correction to the minutes and it was moved they be approved. The motion carried and the minutes were approved.

THERAPEUTIC CLASS REVIEWS: Ms. Clark then turned the meeting over to Dr. Pope.

Dr. Pope thanked Ms. Clark for her cooperation and the Committee for the opportunity to review the selected therapeutic classes.

ACNE AGENTS, TOPICAL

Dr. Pope noted that there was no new clinical information for the class. Dr. Pope then presented the PDL recommendations for the class:

Brand Name	Current PDL Status	PDL Recommendation
10-1 (TOPICAL)	PDL	PDL
ACANYA W/PUMP (TOPICAL)	NPD	NPD
ACZONE (TOPICAL)	NPD	NPD
ADAPALENE CREAM (TOPICAL)	NPD	NPD
ADAPALENE GEL (TOPICAL)	NPD	NPD
AKNE-MYCIN (TOPICAL)	NPD	NPD
ATRALIN (TOPICAL)	NPD	NPD
AZELEX (TOPICAL)	PDL	PDL
BENPROX SUSPENSION (TOPICAL)	PDL	NPD
BENZAC AC (TOPICAL)	PDL	NPD
BENZAC W WASH (TOPICAL)	PDL	NPD
BENZACLIN (TOPICAL)	PDL	PDL
BENZACLIN KIT (TOPICAL)	PDL	NPD
BENZACLIN W/PUMP (TOPICAL)	PDL	PDL
BENZAMYCIN (TOPICAL)	NPD	NPD
BENZEFOAM (TOPICAL)	NPD	NPD
BENZEFOAM ULTRA (TOPICAL)	NPD	NPD
BENZIQU GEL (TOPICAL)	NPD	NPD
BENZIQU SUSPENSION (TOPICAL)	NPD	NPD
BENZOYL PEROXIDE (TOPICAL)	PDL	NPD
BENZOYL PEROXIDE CLEANSER (TOPICAL)	PDL	PDL
BENZOYL PEROXIDE GEL (TOPICAL)	PDL	PDL
BENZOYL PEROXIDE GEL OTC (TOPICAL)	PDL	PDL
BENZOYL PEROXIDE KIT (TOPICAL)	PDL	NPD
BENZOYL PEROXIDE LOTION (TOPICAL)	PDL	NPD
BENZOYL PEROXIDE LOTION OTC (TOPICAL)	PDL	PDL
BENZOYL PEROXIDE MED. PAD (TOPICAL)	PDL	NPD

BENZOYL PEROXIDE MICROSPHERES CLEANSER (TOPICAL)	PDL	NPD
BENZOYL PEROXIDE OTC (TOPICAL)	PDL	NPD
BENZOYL PEROXIDE TOWELETTE (TOPICAL)	PDL	NPD
BENZOYL PEROXIDE/SULFUR (TOPICAL)	NPD	NPD
BENZOYL PEROXIDE/UREA CLEANSER (TOPICAL)	PDL	NPD
BP CLEANSER OTC (TOPICAL)	PDL	NPD
BPO KIT (TOPICAL)	PDL	NPD
BREVOXYL KIT (TOPICAL)	NPD	NPD
CERISA (TOPICAL)	PDL	PDL
CLARIFOAM EF (TOPICAL)	NPD	NPD
CLENIA (TOPICAL)	PDL	NPD
CLINAC BPO (TOPICAL)	PDL	NPD
CLINDACIN PAC KIT (TOPICAL)	NPD	NPD
CLINDAGEL (TOPICAL)	NPD	NPD
CLINDAMYCIN / BENZOYL PEROXIDE (TOPICAL)	NPD	NPD
CLINDAMYCIN PHOSPHATE FOAM (TOPICAL)	PDL	NPD
CLINDAMYCIN PHOSPHATE GEL (TOPICAL)	PDL	PDL
CLINDAMYCIN PHOSPHATE LOTION (TOPICAL)	PDL	PDL
CLINDAMYCIN PHOSPHATE MED. SWAB (TOPICAL)	PDL	NPD
CLINDAMYCIN PHOSPHATE SOLUTION (TOPICAL)	PDL	PDL
DELOS CLEANSER (TOPICAL)	NPD	NPD
DELOS LOTION (TOPICAL)	NPD	NPD
DEQUAM-X (TOPICAL)	PDL	PDL
DEQUAM-X OTC (TOPICAL)	PDL	PDL
DIFFERIN CREAM (TOPICAL)	NPD	NPD
DIFFERIN GEL (TOPICAL)	NPD	NPD
DIFFERIN LOTION (TOPICAL)	NPD	NPD
DUAC CS KIT (TOPICAL)	NPD	NPD
EPIDUO (TOPICAL)	NPD	NPD
ERYTHROMYCIN GEL (TOPICAL)	PDL	PDL
ERYTHROMYCIN MED. SWAB (TOPICAL)	PDL	NPD
ERYTHROMYCIN SOLUTION (TOPICAL)	PDL	PDL
ERYTHROMYCIN-BENZOYL PEROXIDE (TOPICAL)	NPD	NPD
EVOCLIN (TOPICAL)	NPD	NPD
INOVA (TOPICAL)	PDL	NPD
INOVA 4/1 (TOPICAL)	PDL	NPD
INOVA 8/2 (TOPICAL)	PDL	NPD
INVISIBLE ACNE OTC (TOPICAL)	PDL	PDL
LAVOCLEN CLEANSER (TOPICAL)	NPD	NPD
LAVOCLEN KIT (TOPICAL)	NPD	NPD
NEOBENZ MICRO KIT (TOPICAL)	NPD	NPD
NEOBENZ MICRO SD (TOPICAL)	NPD	NPD
NUOX (TOPICAL)	PDL	NPD

PACNEX HP (TOPICAL)	NPD	NPD
PANOXYL 10 OTC (TOPICAL)	PDL	PDL
PANOXYL 5 OTC (TOPICAL)	PDL	PDL
PLEXION SCT CREAM (TOPICAL)	NPD	NPD
PRASCION CLEANSER (TOPICAL)	NPD	NPD
PRASCION RA CREAM (TOPICAL)	NPD	NPD
RETIN-A MICRO (TOPICAL)	PDL	PDL
RETIN-A MICRO PUMP (TOPICAL)	PDL	PDL
ROSANIL CLEANSER (TOPICAL)	NPD	NPD
ROSANIL KIT (TOPICAL)	NPD	NPD
SASTID (TOPICAL)	NPD	NPD
SE 10-5 SS (TOPICAL)	NPD	NPD
SE BPO CLEANSER (TOPICAL)	NPD	NPD
SEB-PREV (TOPICAL)	NPD	NPD
SSS 10-4 (TOPICAL)	PDL	NPD
SULFACETAMIDE / SULFUR / UREA CLEANSER (TOPICAL)	PDL	NPD
SULFACETAMIDE / SULFUR CLEANSER (TOPICAL)	PDL	NPD
SULFACETAMIDE / SULFUR LOTION (TOPICAL)	PDL	PDL
SULFACETAMIDE / SULFUR MED. PAD (TOPICAL)	NPD	NPD
SULFACETAMIDE / SULFUR SUSPENSION (TOPICAL)	PDL	NPD
SULFACETAMIDE CLEANSER (TOPICAL)	NPD	NPD
SULFACETAMIDE SUSPENSION (TOPICAL)	NPD	NPD
SULFOAM (TOPICAL)	NPD	NPD
SULPHO-LAC (TOPICAL)	NR	PDL
SUMADAN (TOPICAL)	NR	NPD
TAZORAC CREAM (TOPICAL)	NPD	NPD
TAZORAC GEL (TOPICAL)	NPD	NPD
TRETINOIN CREAM (TOPICAL)	NPD	NPD
TRETINOIN GEL (TOPICAL)	NPD	NPD
TRETINOIN/EMOLLIENT CREAM (TOPICAL)	NPD	NPD
VELTIN (TOPICAL)	NPD	NPD
ZIANA (TOPICAL)	NPD	NPD

There were no speakers for this class and there was no significant discussion among the Committee members. Dr. Weiland made a motion to accept Provider Synergies' recommendations as presented. The motion was seconded by Dr. Dickey. The motion passed unanimously.

ANALGESICS, NARCOTIC LONG

Dr. Pope noted that there is no significant new clinical information for this class and that the recommendations had not changed. He then presented the PDL recommendations for the class:

Brand Name	Current PDL Status	PDL Recommendation
AVINZA (ORAL)	NPD	NPD
BUTRANS (TRANSDERM)	NPD	NPD
CONZIP (ORAL)	NPD	NPD
DURAGESIC MATRIX (TRANSDERM.)	NPD	NPD
DURAGESIC MATRIX (TRANSDERM.)	NPD	NPD
EXALGO (ORAL)	NPD	NPD
FENTANYL (TRANSDERM)	PDL	PDL
KADIAN (ORAL)	PDL	PDL
METHADONE CONC (ORAL)	PDL	PDL
METHADONE SOL TABLET (ORAL)	PDL	PDL
METHADONE SOUTION (ORAL)	PDL	PDL
METHADONE TABLET (ORAL)	PDL	PDL
MORPHINE ER (ORAL)	PDL	PDL
NUCYNTA ER (ORAL)	NPD	NPD
OPANA ER (ORAL)	NPD	NPD
ORAMORPH SR (ORAL)	PDL	PDL
OXYCODONE ER (ORAL)	NPD	NPD
OXYCONTIN (ORAL)	NPD	NPD
OXYMORPHONE ER (ORAL)	NPD	NPD
RYZOLT (ORAL)	NPD	NPD
TRAMADOL ER (ORAL)	NPD	NPD
ULTRAM ER (ORAL)	NPD	NPD

Victoria Valdez of Johnson & Johnson spoke on behalf of Nucynta ER.

There was no significant discussion among Committee members. Dr. Azomani made a motion to accept Provider Synergies' recommendations as presented. The motion was seconded by Ms. Wilbanks. The motion passed with one abstention – Dr. Dickey.

ANALGESICS, NARCOTIC SHORT

Dr. Pope noted that this class some newer products including, Trezix, Primalev and Xolox. It was noted that none of the products presents a distinct clinical advantage over other members of the class, and new products are reformulations of existing components in differing concentrations. Otherwise there was no new clinical information for this class. Dr. Pope presented the following PDL recommendations for consideration:

Brand Name	Current PDL Status	PDL Recommendation
ABSTRAL (SUBLINGUAL)	NPD	NPD
APAP / CODEINE ELIXIR (ORAL)	PDL	PDL
APAP / CODEINE TABLET (ORAL)	PDL	PDL
BUTALBITAL COMPOUND W/CODEINE (ORAL)	NPD	NPD
BUTORPHANOL TARTRATE (NASAL)	NR	NPD
CAPITAL W-CODEINE (ORAL)	NPD	NPD
COCET (ORAL)	NPD	NPD
COCET PLUS (ORAL)	PDL	PDL
CODEINE (ORAL)	PDL	PDL
DIHYDROCODEINE / APAP / CAFFEINE (ORAL)	PDL	PDL
DILAUDID LIQUID (ORAL)	NPD	NPD
FENTANYL (BUCCAL)	NPD	NPD
FENTORA (BUCCAL)	NPD	NPD
HYCET (ORAL)	NPD	NPD
HYDROCODONE / APAP CAPSULE (ORAL)	PDL	PDL
HYDROCODONE / APAP SOLUTION (ORAL)	PDL	PDL
HYDROCODONE / APAP TABLET (ORAL)	PDL	PDL
HYDROCODONE / IBUPROFEN (ORAL)	PDL	PDL
HYDROMORPHONE SUPP.RECT (ORAL)	PDL	PDL
HYDROMORPHONE TABLET (ORAL)	PDL	PDL
IBUDONE (ORAL)	PDL	PDL
IBUDONE (ORAL) (NO RESTRICTIONS)	PDL	PDL
LEVORPHANOL (ORAL)	NPD	NPD

MAGNACET (ORAL)	NPD	NPD
MEPERIDINE SOLUTION (ORAL)	PDL	PDL
MEPERIDINE TABLET (ORAL)	PDL	PDL
MORPHINE IR SOLUTION (ORAL)	PDL	PDL
MORPHINE IR SUPP.RECT (ORAL)	PDL	PDL
MORPHINE IR TABLET (ORAL)	PDL	PDL
NUCYNTA (ORAL)	NPD	NPD
ONSOLIS (BUCCAL)	NPD	NPD
OXYCODONE / APAP CAPSULE (ORAL)	PDL	PDL
OXYCODONE / APAP TABLET (ORAL)	PDL	PDL
OXYCODONE / ASA BRAND (ORAL)	PDL	PDL
OXYCODONE / IBUPROFEN (ORAL)	PDL	PDL
OXYCODONE CAPSULE (ORAL)	PDL	PDL
OXYCODONE CONC (ORAL)	PDL	PDL
OXYCODONE SOLUTION (ORAL)	PDL	PDL
OXYCODONE TABLET (ORAL)	PDL	PDL
OXYMORPHONE (ORAL)	NPD	NPD
PENTAZOCINE / APAP (ORAL)	PDL	PDL
PENTAZOCINE / NALOXONE (ORAL)	NPD	NPD
PRIMALEV (ORAL)	NPD	NPD
REPREXAIN (ORAL)	NPD	NPD
ROXICET CAPSULE (ORAL)	PDL	PDL
ROXICET TABLET (ORAL)	PDL	PDL
ROXICODONE TABLET (ORAL)	PDL	PDL
RYBIX ODT (ORAL)	NPD	NPD
SYNALGOS-DC (ORAL)	NPD	NPD
TRAMADOL (ORAL)	PDL	PDL
TRAMADOL / APAP (ORAL)	PDL	PDL
TREZIX (ORAL)	PDL	PDL
TYLOX (ORAL)	NPD	NPD
XOLOX (ORAL)	NPD	NPD

ZAMICET (ORAL)	NPD	NPD
ZOLVIT (ORAL)	NPD	NPD
ZYDONE (ORAL)	PDL	PDL

There were no presenters or advocates for this class.

Ms. Wilbanks made a motion to accept the recommendations for the class as presented by Provider Synergies. Dr. Azomani seconded the motion, which passed unanimously.

ANALGESICS-ANESTHETICS, TOPICAL

Dr. Pope indicated there were neither new entries into the class nor any new clinical information. Dr. Pope did reveal this class may be dispersed to other classes in the future. Dr. Pope presented the following PDL recommendations for consideration:

Brand Name	Current PDL Status	PDL Recommendation
FLECTOR (TOPICAL)	PDL	PDL
LIDODERM (TOPICAL)	PDL	PDL
PENNSAID (TOPICAL)	NPD	NPD
VOLTAREN (TOPICAL)	PDL	PDL

There were no presenters or manufacturer representative speakers for this class.

The Committee had little discussion of this class. Dr. Harper made a motion to accept Provider Synergies' recommendations. The motion was seconded by Dr. Dickey. The motion passed unanimously.

ANTIFUNGALS, TOPICAL

Dr. Pope noted that there is no significant new clinical information for this class and that the recommendations were not based on clinical significance, rather cost. Dr. Pope then presented the PDL recommendations to the Committee:

Brand Name	Current Status	PDL	PDL Recommendation
BENSAL HP (TOPICAL)	NPD		NPD
CICLODAN KIT (TOPICAL)	NPD		NPD
CICLOPIROX CREAM (TOPICAL)	PDL		PDL
CICLOPIROX GEL (TOPICAL)	PDL		PDL

CICLOPIROX KIT (TOPICAL)	PDL	NPD
CICLOPIROX SHAMPOO (TOPICAL)	PDL	NPD
CICLOPIROX SOLUTION (TOPICAL)	PDL	NPD
CICLOPIROX SUSPENSION (TOPICAL)	PDL	PDL
CLOTRIMAZOLE CREAM OTC (TOPICAL)	PDL	PDL
CLOTRIMAZOLE CREAM RX (TOPICAL)	PDL	PDL
CLOTRIMAZOLE SOLUTION OTC (TOPICAL)	PDL	PDL
CLOTRIMAZOLE SOLUTION RX (TOPICAL)	PDL	PDL
CLOTRIMAZOLE-BETAMETHASONE CREAM (TOPICAL)	PDL	PDL
CLOTRIMAZOLE-BETAMETHASONE LOTION (TOPICAL)	PDL	NPD
CNL 8 KIT (TOPICAL)	NPD	NPD
ECONAZOLE (TOPICAL)	PDL	PDL
ERTACZO (TOPICAL)	NPD	NPD
EXELDERM CREAM (TOPICAL)	NPD	NPD
EXELDERM SOLUTION (TOPICAL)	NPD	NPD
EXTINA (TOPICAL)	NPD	NPD
KETOCON + PLUS (TOPICAL)	NPD	NPD
KETOCONAZOLE CREAM (TOPICAL)	PDL	PDL
KETOCONAZOLE FOAM (TOPICAL)	NPD	NPD
KETOCONAZOLE SHAMPOO (TOPICAL)	PDL	PDL
LAMISIL SOLUTION (TOPICAL)	PDL	NPD
LOTRIMIN AF CREAM OTC (TOPICAL)	PDL	PDL
MENTAX (TOPICAL)	NPD	NPD
MICONAZOLE CREAM OTC (TOPICAL)	PDL	PDL
NAFTIN CREAM (TOPICAL)	PDL	NPD
NAFTIN GEL (TOPICAL)	PDL	NPD
NYSTATIN CREAM (TOPICAL)	PDL	PDL
NYSTATIN OINT (TOPICAL)	PDL	PDL
NYSTATIN POWDER (TOPICAL)	PDL	PDL

NYSTATIN-TRIAMCINOLONE CREAM (TOPICAL)	PDL	PDL
NYSTATIN-TRIAMCINOLONE OINT (TOPICAL)	PDL	PDL
OXISTAT CREAM (TOPICAL)	NPD	NPD
OXISTAT LOTION (TOPICAL)	NPD	NPD
PEDIADERM AF (TOPICAL)	NPD	NPD
TERBINAFINE CREAM OTC (TOPICAL)	PDL	PDL
TOLNAFTATE AERO POWDER OTC (TOPICAL)	PDL	NPD
TOLNAFTATE CREAM OTC (TOPICAL)	PDL	PDL
TOLNAFTATE POWDER OTC (TOPICAL)	PDL	PDL
VUSION (TOPICAL)	NPD	NPD
XOLEGEL (TOPICAL)	NPD	NPD

No public testimony on this class was provided nor was there Committee discussion.

Dr. Voulters made a motion to approve the recommendations as presented by Provider Synergies. The motion was seconded by Dr. Weiland and passed unanimously.

ANTIHYPURICEMICS

Dr. Pope noted again there were no new entries into the market for this class. Dr. Pope, also indicated that the recommendations for this class had not changed from last year. Dr. Minor did note she had some issues with the class TCR and that some of the clinical study conclusions needed to be re-evaluated. Dr. Pope presented the PDL recommendations for this class:

Brand Name	Current PDL Status	PDL Recommendation
ALLOPURINOL (ORAL)	PDL	PDL
COLCRYS (ORAL)	PDL	PDL
PROBENECID (ORAL)	PDL	PDL
PROBENECID / COLCHICINE (ORAL)	PDL	PDL
ULORIC (ORAL)	NPD	NPD

There were no presenters giving public testimony for this class.

Dr. Azomani made the motion to accept the recommendations, which was seconded by Ms. Weiland. The motion passed unanimously.

ANTIMIGRAINE AGENTS

Dr. Pope related that this group does have two new products, Sumavel, which is a newer formulation of sumatriptan and Cambia, diclofenac, an NSAID. Dr. Pope also indicated that this is a class that will soon become a generic first class. Dr. Pope stated that there was no significant new clinical information for this class and only one change in recommendations. Dr. Pope presented the PDL recommendations to the Committee:

Brand Name	Current Status	PDL	PDL Recommendation
AXERT (ORAL)	NPD		NPD
CAMBIA (ORAL)	NPD		NPD
FROVA (ORAL)	NPD		NPD
IMITREX (NASAL)	NPD		NPD
IMITREX KIT (SUBCUTANE.)	NPD		NPD
MAXALT MLT (ORAL)	NPD		NPD
MAXALT TABLET (ORAL)	NPD		NPD
NARATRIPTAN (ORAL)	NPD		NPD
RELPAX (ORAL)	PDL		PDL
SUMATRIPTAN (NASAL)	PDL		PDL
SUMATRIPTAN (ORAL)	PDL		PDL
SUMATRIPTAN DISP SYRIN (SUBCUTANE.)	PDL		PDL
SUMATRIPTAN KIT (SUBCUTANE.)	PDL		PDL
SUMATRIPTAN PEN INJCTR (SUBCUTANE.)	PDL		PDL
SUMATRIPTAN VIAL (SUBCUTANE.)	PDL		PDL
SUMAVEL DOSEPRO (SUBCUTANE.)	NPD		NPD
TREXIMET (ORAL)	PDL		NPD
ZOMIG (NASAL)	NPD		NPD
ZOMIG (ORAL)	NPD		NPD
ZOMIG ZMT (ORAL)	NPD		NPD

Ken Linsky of GlaxoSmithKline spoke on behalf keeping Treximet as a preferred product.

The Committee held some discussion on the merits of Treximet remaining as a preferred agent. Dr. Voulters made a motion to accept the PDL recommendations as presented.

The motion was seconded by Dr. Weiland and passed with Dr Azomani abstaining.

ANTIPARASITICS, TOPICAL

Dr. Pope stated there are a variety methods of treating head lice including use of the agents in this class. Dr. Pope stated that there was no significant new clinical information for this class and no recommended changes. Dr. Pope presented the PDL recommendations:

Brand Name	Current PDL Status	PDL Recommendation
EURAX CREAM (TOPICAL)	PDL	PDL
EURAX LOTION (TOPICAL)	PDL	PDL
LINDANE LOTION (TOPICAL)	NPD	NPD
LINDANE SHAMPOO (TOPICAL)	NPD	NPD
MALATHION (TOPICAL)	PDL	PDL
MALATHION BRAND (TOPICAL)	PDL	PDL
NATROBA (TOPICAL)	NPD	NPD
OVIDE (TOPICAL)	NPD	NPD
PERMETHRIN (TOPICAL)	PDL	PDL
PERMETHRIN OTC (TOPICAL)	PDL	PDL
PIPERONYL BUTOXIDE/PYRETHRINS LIQUID OTC (TOPICAL)	PDL	PDL
ULESFIA (TOPICAL)	NPD	NPD

David Beddingfield of Taro Pharmaceuticals was listed to speak on behalf of Ovide, but decided to yield his time back to the Committee.

Ms. Wilbanks made a motion to accept the recommendations as presented from Dr. Pope. The motion was seconded by Dr. Azomani. The motion passed without dissent.

ANTIVIRALS, TOPICAL

Dr. Pope stated that there was no significant new clinical information for this class and no recommended changes for this class. Dr. Pope presented the PDL recommendations to the Committee:

Brand Name	Current PDL Status	PDL Recommendation
DENAVIR (TOPICAL)	PDL	PDL
XERESE (TOPICAL)	NPD	NPD
ZOVIRAX CREAM (TOPICAL)	NPD	NPD
ZOVIRAX OINTMENT (TOPICAL)	PDL	PDL

There were no presenters or advocates signed up to speak on this class. .

There was no significant discussion among Committee members.

Dr. Voulters made a motion to accept the recommendations as presented. The motion was seconded by Dr. Harper and passed unanimously.

CYTOKINE AND CAM ANTAGONISTS

Dr. Pope stated the new clinical information for this class which consists on increased indications for several products in this class as well as one new self-injection form of Orencia. Dr. Pope also related that clinically these drugs are all similar in efficacy if dosed according to prescribing guidelines. Dr. Pope presented the PDL class recommendations to the Committee:

Brand Name	Current Status	PDL	PDL Recommendation
ACTEMRA (INJECTION)	NPD		NPD
AMEVIVE (INJECTION)	NPD		NPD
CIMZIA KIT (INJECTION)	NPD		NPD
CIMZIA SYRINGE KIT (INJECTION)	NPD		NPD
ENBREL DISP SYRINGE (INJECTION)	PDL		PDL
ENBREL KIT (INJECTION)	PDL		PDL
ENBREL PEN (INJECTION)	PDL		PDL
HUMIRA KIT (INJECTION)	PDL		PDL
HUMIRA PEN IJ KIT (INJECTION)	PDL		PDL
KINERET (INJECTION)	PDL		PDL
ORENCIA (INJECTION)	NPD		NPD
ORENCIA (SUB-Q)	NPD		NPD

REMICADE (INJECTION)	NPD	NPD
SIMPONI DISP SYRINGE (INJECTION)	NPD	NPD
SIMPONI PEN INJECTER (INJECTION)	NPD	NPD
STELARA DISP SYRINGE (INJECTION)	NPD	NPD
STELARA VIAL (INJECTION)	NPD	NPD

There were several manufacturer representatives that gave public testimony for this class. These included: Dr. Melissa McAllister of UCB on behalf of Cimzia; Dr. Megan Jones of Johnson & Johnson on behalf of Simponi; Dr. Andrea Herrera of Abbott Labs on behalf of Humira and Dr. Alissa Hicks of Amgen on behalf of Enbrel, the latter two both yielded their time back to the Committee.

Dr. Azomani made a motion to accept the recommendations as listed by Provider Synergies. The motion was seconded by Dr. Mitchell. The motion passed with all members voting in favor.

FIBROMYALGIA

Dr. Pope stated that there were no recommended changes for this class and no new entries indicated for use in Fibromyalgia. Dr. Pope related the agents available as well as their other indications and uses. Dr. Pope presented the PDL recommendations to the Committee:

Brand Name	Current PDL Status	PDL Recommendation
CYMBALTA (ORAL)	NPD	NPD
LYRICA (ORAL)	PDL	PDL
SAVELLA (ORAL)	PDL	PDL
SAVELLA DS PK (ORAL)	PDL	PDL

There were several manufacturer representatives listed to give public testimony for this class. These included: Dr. Jenny Blackham of Lilly, USA who spoke on behalf of Cymbalta; Jolan Rosenthal of Forest Pharmaceuticals on behalf of Savella, who yielded time back to the Committee; and Dr. LeeAnn Griffin of Pfizer on behalf of Lyrica who also yielded back time to the Committee.

Dr. Weiland made a motion to approve the PDL as recommended. The motion was seconded by Ms. Wilbanks and was passed unanimously.

Following the vote on Fibromyalgia agents, the Committee broke for lunch.

IMMUNOMODULATORS, ATOPIC DERMATITIS

Dr. Pope stated that there was no significant new clinical information for this class and no new agents. Dr. Pope also stated there was one recommended change in this class. Dr. Pope presented the PDL scenario recommendations to the Committee:

Brand Name	Current PDL Status	PDL Recommendation
ELIDEL (TOPICAL)	PDL	PDL
PROTOPIC (TOPICAL)	PDL	NPD

Marilyn Ripoli of Astellas Pharmaceuticals spoke on behalf of Protopic requesting it remain a preferred product.

Dr. Azomani made a motion not to accept recommendations and keep the status quo for the class. Dr. Norwood seconded the motion, which passed unanimously.

NSAIDS

Dr. Pope stated that there was no significant new clinical information for this class and no new agents for consideration. Dr. Pope presented the PDL recommendations to the Committee for consideration:

Brand Name	Current PDL Status	PDL Recommendation
ARTHROTEC (ORAL)	NPD	NPD
CELEBREX (ORAL)	NPD	NPD
DICLOFENAC (ORAL)	PDL	PDL
DICLOFENAC POTASSIUM (ORAL)	PDL	PDL
DICLOFENAC SR (ORAL)	PDL	NPD
DIFLUNISAL (ORAL)	NPD	NPD
ETODOLAC CAPSULE (ORAL)	PDL	NPD
ETODOLAC TAB SR (ORAL)	PDL	NPD
ETODOLAC TABLET (ORAL)	PDL	PDL
FENOPROFEN (ORAL)	PDL	NPD
FLURBIPROFEN (ORAL)	PDL	PDL
IBUPROFEN SUSPENSION (ORAL)	PDL	PDL
IBUPROFEN SUSPENSION OTC (ORAL)	NR	PDL
IBUPROFEN TABLET (ORAL)	PDL	PDL
INDOCIN (RECTAL)	NPD	NPD
INDOCIN SUSPENSION (ORAL)	NPD	NPD

INDOMETHACIN CAPSULE (ORAL)	PDL	PDL
INDOMETHACIN CAPSULE ER (ORAL)	PDL	NPD
KETOPROFEN (ORAL)	PDL	PDL
KETOPROFEN ER (ORAL)	PDL	NPD
KETOROLAC (ORAL)	PDL	PDL
MECLOFENAMATE (ORAL)	NPD	NPD
MELOXICAM SUSPENSION (ORAL)	PDL	PDL
MELOXICAM TABLET (ORAL)	PDL	NPD
MOBIC SUSPENSION (ORAL)	NPD	NPD
NABUMETONE (ORAL)	NPD	NPD
NALFON (ORAL)	NPD	NPD
NAPRELAN (ORAL)	NPD	NPD
NAPROSYN SUSPENSION (ORAL)	NPD	NPD
NAPROXEN SODIUM (ORAL)	PDL	PDL
NAPROXEN SUSPENSION (ORAL)	PDL	PDL
NAPROXEN TABLET (ORAL)	PDL	PDL
OXAPROZIN (ORAL)	PDL	NPD
PIROXICAM (ORAL)	PDL	PDL
PONSTEL (ORAL)	NPD	NPD
SPRIX (NASAL)	NPD	NPD
SULINDAC (ORAL)	PDL	PDL
TOLMETIN SODIUM CAPSULE (ORAL)	NPD	NPD
TOLMETIN SODIUM TABLET (ORAL)	NPD	NPD
VIMOVO (ORAL)	NPD	NPD
ZIPSOR (ORAL)	NPD	NPD

Dr. LeeAnn Griffin of Pfizer spoke on behalf of Celebrex requesting it be made a preferred product.

Dr. Voulters made a motion to accept recommendations as presented. Dr. Weiland seconded the motion, which passed with one opposition vote, Ms. Wilbanks..

OPIATE DEPENDENCE TREATMENTS

Dr. Pope stated that there was no significant new clinical information for this class and no new product of note for discussion. Dr. Pope presented the PDL recommendations to the Committee:

Brand Name	Current Status	PDL	PDL Recommendation
BUPRENORPHINE HCL (SUBLINGUAL)	NPD		NPD
SUBOXONE FILM (SUBLINGUAL)	NPD		PDL
SUBOXONE TABLETS (SUBLINGUAL)	NPD		PDL

There were no public presentations for this class and no substantive Committee discussion.

Dr. Weiland made a motion to accept the recommendations presented by Dr. Pope. The motion was seconded by Dr. Tingle and accepted unanimously.

SKELETAL MUSCLE RELAXANTS

Dr. Pope stated there were no new entries for this class and no significant new clinical information. Dr. Pope presented the PDL scenario recommendation to the Committee:

Brand Name	Current Status	PDL	PDL Recommendation
AMRIX (ORAL)	NPD		NPD
BACLOFEN (ORAL)	PDL		PDL
CARISOPRODOL (ORAL)	NPD		NPD
CARISOPRODOL 250 MG (ORAL)	NPD		NPD
CARISOPRODOL COMPOUND (ORAL)	NPD		NPD
CHLORZOXAZONE (ORAL)	PDL		PDL
CYCLOBENZAPRINE (ORAL)	PDL		PDL
CYCLOBENZAPRINE ER (ORAL)	NPD		NPD
DANTROLENE SODIUM (ORAL)	PDL		NPD
FEXMID (ORAL)	NPD		NPD
METAXALONE (ORAL)	NPD		NPD
METHOCARBAMOL (ORAL)	PDL		PDL
ORPHENADRINE (ORAL)	NPD		NPD
ORPHENADRINE COMPOUND (ORAL)	NPD		NPD
SKELAXIN (ORAL)	NPD		NPD
SOMA 250 MG (ORAL)	NPD		NPD
TIZANIDINE (ORAL)	PDL		PDL
ZANAFLEX CAPSULE (ORAL)	NPD		NPD

There was no public testimony for this class.

Ms. Wilbanks made a motion to accept the recommendations as listed. The motion was seconded by Dr. Weiland. All members voted in favor of the recommendations.

STEROIDS, TOPICAL HIGH

Dr. Pope stated there were no new entries for this class and no significant new clinical information. Dr. Pope presented the following PDL recommendations:

Brand Name	Current Status	PDL	PDL Recommendation
AMCINONIDE CREAM (TOPICAL)	PDL		PDL
AMCINONIDE LOTION (TOPICAL)	PDL		PDL
AMCINONIDE OINT. (TOPICAL)	PDL		NPD
BETAMET DIPROP / PROP GLY CREAM (TOPICAL)	PDL		NPD
BETAMET DIPROP / PROP GLY LOTION (TOPICAL)	PDL		NPD
BETAMET DIPROP / PROP GLY OINT. (TOPICAL)	PDL		NPD
BETAMETHASONE DIPROPIONATE CREAM (TOPICAL)	PDL		PDL
BETAMETHASONE DIPROPIONATE GEL (TOPICAL)	PDL		PDL
BETAMETHASONE DIPROPIONATE LOTION (TOPICAL)	PDL		PDL
BETAMETHASONE DIPROPIONATE OINT. (TOPICAL)	PDL		NPD
BETAMETHASONE VALERATE CREAM (TOPICAL)	PDL		PDL
BETAMETHASONE VALERATE LOTION (TOPICAL)	PDL		PDL
BETAMETHASONE VALERATE OINT. (TOPICAL)	PDL		PDL
DESOXIMETASONE CREAM (TOPICAL)	NPD		NPD
DESOXIMETASONE GEL (TOPICAL)	NPD		NPD
DESOXIMETASONE OINT. (TOPICAL)	NPD		NPD
DIFLORASONE DIACETATE CREAM (TOPICAL)	NPD		NPD

DIFLORASONE DIACETATE OINT. (TOPICAL)	NPD	NPD
FLUOCINONIDE CREAM (TOPICAL)	PDL	PDL
FLUOCINONIDE EMOLLIENT (TOPICAL)	PDL	PDL
FLUOCINONIDE GEL (TOPICAL)	PDL	PDL
FLUOCINONIDE OINT. (TOPICAL)	PDL	PDL
FLUOCINONIDE SOLUTION (TOPICAL)	PDL	PDL
HALOG CREAM (TOPICAL)	NPD	NPD
HALOG OINT. (TOPICAL)	NPD	NPD
KENALOG AEROSOL (TOPICAL)	NPD	NPD
TOPICORT CREAM (TOPICAL)	NPD	NPD
TOPICORT GEL (TOPICAL)	NPD	NPD
TOPICORT LP CREAM (TOPICAL)	NPD	NPD
TOPICORT LP OINT. (TOPICAL)	NPD	NPD
TOPICORT OINT. (TOPICAL)	NPD	NPD
TRIAMCINOLONE ACETONIDE CREAM (TOPICAL)	PDL	PDL
TRIAMCINOLONE ACETONIDE LOTION (TOPICAL)	PDL	PDL
TRIAMCINOLONE ACETONIDE OINT. (TOPICAL)	PDL	PDL
VANOS (TOPICAL)	NPD	NPD

There was no public testimony for this class.

Dr. Harper made a motion to approve the recommendations. The motion was seconded by Dr. Brown and passed unanimously.

STEROIDS, TOPICAL LOW

Dr. Pope stated that there was no significant new clinical information nor were there any new branded products for the class. Dr. Pope presented two PDL recommendations for the Committee to consider:

Brand Name	Current PDL Status	PDL Recommendation
ALCLOMETASONE DIPROPIONATE CREAM (TOPICAL)	NPD	NPD
ALCLOMETASONE DIPROPIONATE OINT. (TOPICAL)	NPD	NPD

CAPEX SHAMPOO (TOPICAL)	PDL	PDL
DERMA-SMOOTHIE-FS (TOPICAL)	NPD	NPD
DESONATE GEL TOPICAL)	NPD	NPD
DESONIDE CREAM (TOPICAL)	PDL	PDL
DESONIDE LOTION (TOPICAL)	PDL	NPD
DESONIDE OINT. (TOPICAL)	PDL	PDL
DESOWEN CREAM KIT (TOPICAL)	NPD	NPD
DESOWEN LOTION (TOPICAL)	NPD	PDL
DESOWEN LOTION KIT (TOPICAL)	NPD	NPD
DESOWEN OINT. KIT (TOPICAL)	NPD	NPD
HYDROCORTISONE / ALOE GEL (TOPICAL)	PDL	PDL
HYDROCORTISONE / ALOE LOTION (TOPICAL)	PDL	PDL
HYDROCORTISONE / MIN OIL / PET OINT. (TOPICAL)	PDL	PDL
HYDROCORTISONE ACETATE / UREA (TOPICAL)	NPD	NPD
HYDROCORTISONE CREAM (TOPICAL)	PDL	PDL
HYDROCORTISONE CREAM OTC (TOPICAL)	PDL	PDL
HYDROCORTISONE LOTION (TOPICAL)	PDL	NPD
HYDROCORTISONE LOTION OTC (TOPICAL)	PDL	PDL
HYDROCORTISONE OINT. (TOPICAL)	PDL	PDL
HYDROCORTISONE OINT. OTC (TOPICAL)	PDL	PDL
HYDROCORTISONE WITH ALOE (TOPICAL)	NPD	NPD
NUZON (TOPICAL)	NPD	NPD
PEDIADERM HC (TOPICAL)	NPD	NPD
PEDIADERM TA (TOPICAL)	NPD	NPD
TEXACORT (TOPICAL)	NPD	NPD
VERDESO (TOPICAL)	NPD	NPD

Lois Drotar of Hill Dermaceuticals spoke on behalf of Derma-Smoothie FS requesting it be made a preferred product.

Ms. Tingle made a motion to approve the recommendations contained in scenario one. The motion was seconded by Dr. Azomani. The motion was approved unanimously.

STEROIDS, TOPICAL MEDIUM

Dr. Pope stated that there was neither significant new clinical information for this class nor any new recommendations. Dr. Pope presented the PDL recommendations to the Committee:

Brand Name	Current PDL Status	PDL Recommendation
-------------------	---------------------------	---------------------------

CLODERM (TOPICAL)	NPD	NPD
CORDRAN TAPE (TOPICAL)	NPD	NPD
CUTIVATE LOTION (TOPICAL)	NPD	NPD
DERMATOP CREAM (TOPICAL)	NPD	NPD
DERMATOP OINT. (TOPICAL)	NPD	NPD
FLUOCINOLONE ACETONIDE CREAM (TOPICAL)	PDL	PDL
FLUOCINOLONE ACETONIDE OINT. (TOPICAL)	PDL	PDL
FLUOCINOLONE ACETONIDE SOLUTION (TOPICAL)	PDL	PDL
FLUTICASONE PROPIONATE CREAM (TOPICAL)	NPD	NPD
FLUTICASONE PROPIONATE OINT. (TOPICAL)	NPD	NPD
HYDROCORTISONE BUTYRATE CREAM (TOPICAL)	PDL	PDL
HYDROCORTISONE BUTYRATE CREAM BRAND (TOPICAL)	PDL	PDL
HYDROCORTISONE BUTYRATE OINT. (TOPICAL)	PDL	PDL
HYDROCORTISONE BUTYRATE OINT. BRAND (TOPICAL)	PDL	PDL
HYDROCORTISONE BUTYRATE SOLUTION (TOPICAL)	PDL	PDL
HYDROCORTISONE BUTYRATE SOLUTION BRAND (TOPICAL)	PDL	PDL
HYDROCORTISONE VALERATE CREAM (TOPICAL)	PDL	PDL
HYDROCORTISONE VALERATE OINT. (TOPICAL)	PDL	PDL
LUXIQ (TOPICAL)	PDL	NPD
MOMETASONE FUROATE CREAM (TOPICAL)	PDL	PDL
MOMETASONE FUROATE OINT. (TOPICAL)	PDL	PDL
MOMETASONE FUROATE SOLUTION (TOPICAL)	PDL	NPD
MOMEXIN (TOPICAL)	NPD	NPD
PANDEL (TOPICAL)	PDL	PDL
PREDNICARBATE CREAM (TOPICAL)	PDL	PDL

PREDNICARBATE OINT. (TOPICAL)	PDL	NPD
-------------------------------	-----	-----

There was no public testimony for this class.

Ms. Wilbanks made a motion to approve the recommendations as presented. The motion was seconded by Dr. Dickey and passed unanimously by the Committee.

STEROIDS, TOPICAL VERY HIGH

Dr. Pope stated that there was no significant new clinical information for this class nor were there any new agents for review. Dr. Pope presented the PDL recommendations to the Committee:

Brand Name	Current PDL Status	PDL Recommendation
APEXICON E (TOPICAL)	NPD	NPD
CLOBETASOL EMOLLIENT (TOPICAL)	PDL	PDL
CLOBETASOL PROPIONATE CREAM (TOPICAL)	PDL	PDL
CLOBETASOL PROPIONATE FOAM (TOPICAL)	PDL	NPD
CLOBETASOL PROPIONATE GEL (TOPICAL)	PDL	PDL
CLOBETASOL PROPIONATE OINT. (TOPICAL)	PDL	PDL
CLOBETASOL PROPIONATE SOLUTION (TOPICAL)	PDL	PDL
CLOBEX LOTION (TOPICAL)	NPD	NPD
CLOBEX SHAMPOO (TOPICAL)	NPD	NPD
CLOBEX SPRAY (TOPICAL)	NPD	NPD
HALAC (TOPICAL)	NPD	NPD
HALOBETASOL PROPIONATE CREAM (TOPICAL)	PDL	PDL
HALOBETASOL PROPIONATE OINT. (TOPICAL)	PDL	PDL
HALONATE (TOPICAL)	NPD	NPD
OLUX-E (TOPICAL)	NPD	NPD
ULTRAVATE PAC CREAM (TOPICAL)	NPD	NPD

Dr. Dickey made a motion to accept the recommendations as presented by Provider Synergies. The motion was seconded by Mr. Hicks and approved unanimously.

OUT-OF-CYCLE AGENTS

The out-of-cycle drugs being considered for the October 2011 meeting included the

following drugs and therapeutic classes.

Butrans transdermal in the **ANDROGENIC AGENTS** was recommended to be nonpreferred.

Dr. Weiland made a motion to accept the recommendations as presented. The motion was seconded by Ms. Weiland and passed without dissent.

Tekamlo in the **ANGIOTENSIN MODULATOR COMBINATIONS** was recommended to be nonpreferred.

Dr. Julia Compton of Novartis spoke on behalf of Tekamlo requesting it be made a preferred product.

Dr. Azomani made a motion to accept the recommendation as presented. The motion was seconded by Ms. Wilbanks and passed without dissent.

Edarbi in the **ANGIOTENSIN MODULATOR** class was recommended to be nonpreferred.

Dr. Azomani made a motion to accept the recommendation as presented. The motion was seconded by Dr. Weiland and passed without dissent.

Dificid in the **ANTIBIOTICS, GI** was recommended to be nonpreferred.

Dr. Dickey made a motion to accept the recommendation as presented. The motion was seconded by Dr. Harper and passed without dissent.

Xarelto in the **ANTICOAGULANTS** was recommended to be nonpreferred.

Dr. Victoria Valdes of Janssen Pharmaceuticals spoke on behalf of Xarelto.

After Committee discussion of the class and the potential clinical value brought by this new product, Dr. Harper made a motion to have Xarelto be a preferred product on the PDL subject to the time limitations in the product indications; 12 days duration for knee replacement and 35 days duration for hip replacement. The motion was seconded by Dr. Dickey and passed unanimously.

Arcapta in the **BRONCHODILATORS, BETA-AGONISTS** was recommended to be nonpreferred.

Dr. Julia Compton of Novartis spoke on behalf of Arcapta requesting it be made a preferred product.

Dr. Azomani made a motion to accept the recommendation as presented. The motion was seconded by Ms. Wilbanks and passed unanimously.

Daliresp in the **COPD AGENTS** was recommended to be nonpreferred.

Dr. Maggie Murphy of Forest Pharmaceuticals spoke on behalf of Daliresp requesting it be made a preferred product.

Ms. Wilbanks made a motion to accept the recommendation as presented. The motion was seconded by Dr. Weiland and passed without dissent.

Finally, Brilinta in the **PLATELET AGGREGATION INHIBITORS** was recommended to be nonpreferred.

Dr. Azomani made a motion to accept the recommendation as presented. The motion was seconded by Dr. Weiland and passed without dissent.

OLD BUSINESS

The Committee reconsidered the **ANTIDEPRESSANT, OTHER** which was held over from the September meeting pending additional information on the new product in this class, Viibryd. Following a brief review of the new product and other products in the class, Dr. Pope re-presented the recommendations.

Dr. Naissan Hussainzada of Forest Pharmaceuticals spoke on behalf of Viibryd requesting it be made a preferred product. During the discussion of the class, Dr. Azomani stated that Viibryd was an interesting new entry into the class, but clinically and from an efficacy standpoint, it did not necessitate inclusion as a preferred agent.

Dr. Tingle made a motion to accept the original recommendations as presented. The motion was seconded by Dr. Weiland and passed without dissent.

Finally, Provider Synergies, following consultation with the Mississippi DUR project made their recommendations for the Prenatal Vitamin products to be included as preferred products on the Mississippi PDL. Dr. Pope related that the products selected were chosen to provide clinical coverage of various prenatal categories as well as cost-effective choices. The selected products were:

Prenatal Vitamin Products

- Concept DHA
- Dualvit OB
- FoliNatal Plus B
- FoliVan-PRX DHA
- PrenaFirst
- PrenaPlus
- Prenatabs FA
- Prenatal-U
- Prenatal AD
- SE-Natal 19
- Se-Tan DHA
- Taron-C DHA

The Committee expressed the opinion that this was a major step forward and it would greatly benefit the State. The Committee agreed this class would be annually reviewed and they would be interested in the savings realized following implementation.

Dr. Dickey made a motion to accept the original recommendations as presented. The motion was seconded by Dr. Weiland and passed without dissent.

NEXT MEETING DATE

Dr. Pope announced the completion of the PDL review ahead of the scheduled time

frame. Ms. Clark stated that the next P&T Committee meeting is scheduled March 13, 2012.

ADJOURNMENT

There being no further business, Dr. Minor adjourned the meeting.